Immunotherapy on Dialysis — or With Reduced Kidney Function

Most patients with cancer are not candidates for immunotherapy at all, and dialysis is not what decides it. Eligibility comes from the cancer type, the stage and the treatment already given. Where immunotherapy does apply, kidney failure is rarely the reason it is withheld. It is decided case by case, not by a fixed rule.

The reason sits in how these drugs leave the body. Checkpoint inhibitor immunotherapy is a large antibody protein. It is broken down by the body's ordinary protein-handling machinery. It is not filtered into the urine, so the kidney is not the exit route.

The same size that keeps it out of the urine keeps it out of the dialysate. A standard dialysis membrane is built to let small waste molecules through and hold proteins back. The session does not strip the drug out, and no top-up dose is given afterwards.

Chemotherapy is the opposite case, which is where the confusion starts. Several chemotherapy drugs are cleared by the kidney, are dose-adjusted or avoided as filtration falls, and sometimes have to be timed around a dialysis session. Patients who have had chemotherapy carry that expectation forward. It does not transfer to immunotherapy.

There is an honest limit to state. Patients on dialysis, and patients with severe kidney impairment, were excluded from the trials that led to approval of this class. What exists instead is the pharmacology above, published case reports and small series, and the judgement of the treating team. That is a reasonable basis for a case-by-case decision. It is not the same as a proven rule, and no page should pretend otherwise.

One more thing is worth checking before you accept a refusal. Many plans combine immunotherapy with chemotherapy or a targeted drug. Sometimes it is the partner drug, not the immunotherapy, that cannot be given at that level of kidney function. Ask which part of the regimen the objection is actually about.

Nothing on this page decides whether immunotherapy is suitable for you. That comes from the histology report, the stage, your kidney function, your dialysis history and the rest of your medical history, read together by a medical oncologist.

Usually not. Published product information for the checkpoint inhibitor class does not set a dose reduction for mild or moderate reduction in kidney function, because the kidney does not clear these drugs. Severe impairment and established dialysis carry less published evidence, so the dose is confirmed case by case rather than assumed.

What does get planned in detail is everything around the infusion. Four things come up at almost every first visit, and none of them are about the dose.

Which day. Because dialysis does not remove the drug, the infusion does not have to be given after a session for the treatment's sake. Most teams still prefer a non-dialysis day, or the hours after a session, so that you are not doing both on one day and so there is a clear window to observe you afterwards.

Which arm. A fistula or graft arm is protected. Cannulas and blood-pressure cuffs are kept off it, so the infusion and the blood tests use the other arm or an existing central line. Say so at the start of every visit rather than assuming it is on the file.

How much fluid. The infusion and the flush that follows it add volume. If you pass little or no urine, that volume counts inside your allowance between sessions, not on top of it. It is planned with the dialysis unit instead of being discovered at the next weigh-in.

What happens if steroids are needed. If an immune-related reaction develops, steroids are the usual treatment for it. Steroids move blood sugar and blood pressure, which matters more when you are on dialysis. That is a joint decision, and the dialysis prescription may be reviewed alongside it.

Any decision about dose belongs to your oncologist and should be explained to you before the cycle, not after it. If a dose has been changed, ask what was changed and why.

On established dialysis the usual kidney-safety marker is gone. Creatinine no longer reflects immune injury to the kidney. The protocol is rebuilt around what still moves: thyroid, liver, blood counts, glucose, blood pressure, weight between sessions and any residual urine, at baseline and before every cycle.

The schedule below is fixed rather than symptom-driven. The point of a protocol is to find a change before you can feel it, and on dialysis that is harder, because tiredness, breathlessness and poor appetite already have an obvious explanation to blame.

If something changes between cycles, tell the treating team rather than waiting for the next appointment, and do not start, stop or change any medicine at home on the strength of one result. Because immunotherapy is given at CION and dialysis continues at your own unit, ask at the first visit which team is holding the whole picture and how results will be shared between them.

This is a different question with a different risk. A transplanted kidney survives because the immune system is deliberately held back. Checkpoint inhibitor immunotherapy works by releasing immune restraint. The two pull against each other, and rejection of the graft is a recognised outcome.

It is reported often enough in published case series to be treated as a real possibility rather than a rare one. No guideline body treats it as a footnote. This is why the decision is taken by the oncology and transplant teams together, and why it is not something to settle in a single appointment.

The discussion usually covers four things: how well the graft is currently working, whether returning to dialysis would be acceptable to you if it were lost, whether the anti-rejection medicines can be adjusted and monitored around treatment, and whether another treatment could reasonably be tried first. You should hear all four before consenting, not just the first.

The same joint-decision pattern applies to the other people this page is written for. Established autoimmune disease is not an absolute bar to immunotherapy, but it is a genuine reason for caution and a case-by-case conversation with the specialist who already manages it. So is a major comorbidity managed by another team. The logic of an organ-function measure shaping eligibility, rather than the cancer alone, is set out for the liver in Child-Pugh Score and Immunotherapy Eligibility.

CION does not provide dialysis or transplant care. Immunotherapy is given as day care at CION centres, while dialysis and graft monitoring continue with your own nephrology or transplant unit, and the two teams work to one shared plan.

• The same argument for the liver, where a numbered organ-function score is used to decide eligibility — Child-Pugh Score and Immunotherapy Eligibility.
• Where eligibility turns on a marker in the tumour rather than on any organ-function number — Immunotherapy Before Surgery for MSI-High Rectal Cancer.
• Living with a second daily routine alongside treatment raises its own practical questions — the same ground for people with a stoma is covered in Immunotherapy With a Stoma.
• How immunotherapy is delivered, monitored and paid for across our centres — Immunotherapy at CION Cancer Clinics.

Still unsure how any of this applies to your own kidney function or dialysis schedule? Book a free consultation and a medical oncologist will go through both sets of reports with you.